You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

ZELAPAR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Zelapar patents expire, and what generic alternatives are available?

Zelapar is a drug marketed by Bausch and is included in one NDA.

The generic ingredient in ZELAPAR is selegiline hydrochloride. There are seventeen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the selegiline hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Zelapar

A generic version of ZELAPAR was approved as selegiline hydrochloride by MLV on April 1st, 1997.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ZELAPAR?
  • What are the global sales for ZELAPAR?
  • What is Average Wholesale Price for ZELAPAR?
Summary for ZELAPAR
Drug patent expirations by year for ZELAPAR
Drug Prices for ZELAPAR

See drug prices for ZELAPAR

Recent Clinical Trials for ZELAPAR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of South FloridaPhase 4
Bausch Health Americas, Inc.Phase 4
Parkinson's Disease and Movement Disorder Center of Boca RatonPhase 4

See all ZELAPAR clinical trials

US Patents and Regulatory Information for ZELAPAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch ZELAPAR selegiline hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021479-001 Jun 14, 2006 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ZELAPAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch ZELAPAR selegiline hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021479-001 Jun 14, 2006 ⤷  Sign Up ⤷  Sign Up
Bausch ZELAPAR selegiline hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021479-001 Jun 14, 2006 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ZELAPAR

See the table below for patents covering ZELAPAR around the world.

Country Patent Number Title Estimated Expiration
South Africa 9601734 ⤷  Sign Up
Canada 2135062 DOSAGES PHARMACEUTIQUES ET D'AUTRES TYPES (PHARMACEUTICAL AND OTHER DOSAGE FORMS) ⤷  Sign Up
South Korea 0173989 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.